Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
September 30, 2021 16:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical...
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
September 10, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Sept. 10, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that it will be...
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
September 08, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that Markus...
Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
August 12, 2021 07:30 ET
|
Monte Rosa Therapeutics, Inc.
– Completed upsized $255.6 million IPO; cash runway extended into late 2024 – Continued advancement of QuEEN™ protein degradation platform and pipeline of molecular glue degraders, including NEK7...
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
June 23, 2021 20:20 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the...